Real-World Analyses of the Treatment Conditions in Patients Initiating Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor in Taiwan

Aims: Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor is a powerful low density lipoprotein cholesterol (LDL-C)-lowering therapy, but this drug is expensive. This study aimed to describe the real-world treatment conditions in patients initiating PCSK9 inhibitor in Taiwan. Methods: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Lin, Po-Lin, Wu, Yen-Wen, Lin, Chao-Feng, Yeh, Hung-I, Chang, Wei-Ting, Charng, Min-Ji, Huang, Po-Hsun, Lin, Chih-Chan, Lin, Tsung-Hsien, Lin, Wei-Wen, Hsieh, I-Chang, Kuo, Feng-Yu, Chen, Ching-Pei, Li, Yi-Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Japan Atherosclerosis Society 2023
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499444/
https://www.ncbi.nlm.nih.gov/pubmed/36418110
http://dx.doi.org/10.5551/jat.63789

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10499444/
https://www.ncbi.nlm.nih.gov/pubmed/36418110
http://dx.doi.org/10.5551/jat.63789

Ejemplares similares